Osilodrostat

Osilodrostat
Clinical data
Synonyms LCI-699
Routes of
administration		 By mouth
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C13H10FN3
Molar mass 227.24 g·mol−1
3D model (JSmol)

Osilodrostat (INN, USAN) (developmental code name LCI-699) is an orally active, nonsteroidal corticosteroid biosynthesis inhibitor which is under development by Novartis for the treatment of Cushing's syndrome and pituitary ACTH hypersecretion (a specific subtype of Cushing's syndrome).[1][2] It specifically acts as a potent and selective inhibitor of aldosterone synthase (CYP11B2) and at higher dosages of 11β-hydroxylase (CYP11B1).[2] The drug was also under development for the treatment of heart failure, hypertension, and solid tumors, but development was discontinued for these indications.[1] As of 2017, osilodrostat is in phase III and phase II clinical trials for treatment of pituitary ACTH hypersecretion and Cushing's syndrome, respectively.[1]

See also

References

  1. 1 2 3 http://adisinsight.springer.com/drugs/800026342
  2. 1 2 Fleseriu M, Castinetti F (2016). "Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies". Pituitary. 19 (6): 643–653. doi:10.1007/s11102-016-0742-1. PMC 5080363. PMID 27600150.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.